For years, the International Space Station has given researchers a place to ask an extraordinary question: What becomes possible when gravity is removed from the equation?

Now, companies such as Space Tango are asking the next one.

How do we do it at scale?

For almost a decade with Space Tango, Dr. Danielle Rosales, Director of Business Development for Technologies, has watched the company evolve alongside the commercial space industry. What began largely as enabling research aboard the ISS is increasingly focused on transforming discoveries into repeatable processes with commercial potential.

“We’re making the shift from scientific discovery in microgravity to  the practical work of making manufacturing off Earth economically sustainable ,” Dr. Rosales says.

WHEN GRAVITY BECOMES A VARIABLE

Space Tango designs, builds, and automates laboratory systems for off-Earth environments, with much of its current portfolio focused on life sciences.

Microgravity gives researchers something unavailable for sustained periods on Earth: the ability to treat gravity itself as a variable. Changes in fluid dynamics, buoyancy, cellular organization, and other physical and biological processes can reveal new ways to study disease, develop therapies, and manufacture products.

Space Tango-supported work has ranged from plant growth and cell cultures to organoids and thin-film manufacturing for artificial retinas. In one collaboration with UC San Diego, Space Tango developed an automated system for human brain organoids using patient-derived induced pluripotent stem cells.

FROM TEN TO 100,000

Moving from experiment to production changes how success is defined

Space Tango distinguishes scientific success from operational success. Commercial manufacturing requires processes that can be repeated with predictable inputs, outputs, quality, cost, and schedules.

The question becomes less about whether ten organoids can be produced and more about what it would take to produce them reliably for clinical applications at a much larger scales, potentially moving from ten to 100,000.

That means process control, throughput, consistency, logistics, and increasingly, automation.

Automation already allows Space Tango experiments aboard the ISS to control temperature, fluidics, timing, and other conditions while reducing demands on valuable crew time. Uncrewed platforms create opportunities to design research and manufacturing needs without the demands of supporting a crew. Realizing those benefits will require autonomous systems optimized for each platform’s available power and operating constraints.

A LABORATORY THAT CAN MOVE

That autonomy is also helping Space Tango prepare for a post-ISS ecosystem.

Rather than tying its systems to a single destination, the company is pursuing a platform-agnostic approach. Future operations could take place aboard commercial stations,  autonomous vehicles with downmass capability, and eventually lunar or Martian platforms. The result is a scalable laboratory infrastructure designed to move with the market.

And Space Tango is only one layer. Dr. Rosales describes a microgravity supply chain connecting customers, laboratories, destinations, transportation, return capabilities, and ground operations. Commercial success depends on what happens after landing, too; recovering products, preserving integrity, and transferring them to labs or facilities for post-flight processing. Building that cycle will require the capabilities of many companies working across the ecosystem.

For Space Tango, the evolution from discovery to production represents something larger than scaling an experiment. It is the transition from proving what microgravity can do to building the systems that allow us to deliver next-generation therapeutics and materials repeatedly, reliably, and commercially.